ARS Pharmaceuticals Q2 2023 Earnings Report

ARS Pharmaceuticals EPS Results

• Actual EPS: -$0.18
• Consensus EPS: -$0.17
• Beat/Miss: Missed by -$0.01
• One Year Ago EPS: N/A

ARS Pharmaceuticals Revenue Results

• Actual Revenue: $0.01 million
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

ARS Pharmaceuticals Announcement Details

• Quarter: Q2 2023
• Date: 8/10/2023
• Time: N/A
• Conference Call Date: Thursday, August 10, 2023
• Conference Call Time: 7:00AM ET

ARS Pharmaceuticals (NASDAQ:SPRY) (NASDAQ: SPRY) is a clinical-stage biopharmaceutical company dedicated to developing non-opioid therapies for acute pain and allergic conditions. The company’s proprietary drug discovery platform integrates high-throughput peptide screening with a novel vascular targeting technology designed to deliver therapeutic candidates directly to sensory nerve endings. By modulating receptor-mediated pathways involved in pain and itch transmission, ARS aims to provide fast-acting relief with a reduced risk of systemic side effects.

The company’s lead product candidate, CNV301, is in clinical development for emergency and procedural acute pain and is formulated for rapid onset and targeted action. ARS’s allergic disease program includes FRAGM-137, an intranasal peptide designed to alleviate seasonal and perennial allergic rhinitis, and FRAGM-189, which is being explored for skin and ocular manifestations of allergy. These candidates leverage the same platform technologies to address distinct therapeutic areas, underscoring ARS’s commitment to innovation across both pain management and allergy relief.

Founded in 2003 and headquartered in Van Nuys, California, ARS Pharmaceuticals combines in-house development expertise with strategic collaborations to advance its pipeline. The company has entered partnerships and licensing agreements to facilitate global development and commercialization of select candidates. ARS is led by President and Chief Executive Officer David Bourne, who brings extensive biopharma experience in clinical development and corporate strategy. The company’s multidisciplinary team of scientists and clinicians works to translate novel receptor-targeting approaches into safe and effective treatments.